This week in Drug Discovery (2-6 November)
News round-up for 2-6 November 2026 by Diana Turner, Deputy Editor at DDW.
Following the success of the Drug Discovery Innovators and Investors (DDII) London event, which brought together representatives from across the UK life sciences sector, this week’s round-up centres on stories that highlight the importance of collaboration within the sector.
The top stories:
Drug Discovery Innovators and Investors (DDII) conference: Event summary
Held in London under the theme Technology, Scale, and Capital: Advancing UK Drug Discovery and Development, the conference explored how emerging technologies, artificial intelligence (AI), automation and investment could help strengthen the UK’s position as a global centre for pharmaceutical research and development.
EU consortium advances secretome-based therapy for osteoarthritis
The ExoCordOA consortium has announced the launch of a five-year, €13 million project, funded by Horizon Europe to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis.
New company Etcelera unites three drug discovery platforms
Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics.
CasZyme and Cirena to collaborate on developing longer guide RNAs
CasZyme and Cirena have signed an agreement to collaborate on optimising the editing efficiency of CasZyme’s Cas12l CRISPR nuclease in human-relevant applications using Cirena’s synthetic 150-170nt guide RNAs.
German hubs selected for BII cardiometabolic research initiative
BioInnovation Institute (BII) has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative.
